DEA Back to Training School, DEA Bureaucrat Blocks Science While Ignoring their Own TRAINING Manual.
DEA Assistant Administrators and attorney needs a summer assignment, and MMJ BioPharma Cultivation has a suggestion: go back and read your own policy statement and training manual.
Read MoreGross proceeds from offering total $16.6 million.
Financing led by long-term, healthcare-focused institutional investors, including Aytu's largest shareholders Nantahala Capital Management and Stonepine Capital Management, with participation from Aytu management and new institutional shareholders.
Aytu enters the over $22 billion United States prescription major depressive disorder ("MDD") market with the first-in-class oral selective serotonin 5HT1a receptor agonist for adults with MDD.
EXXUA has demonstrated significant improvement in depression symptoms in clinical trials involving more than 5,000 patients and, notably, the incidence of sexual side effects experienced with EXXUA was comparable to placebo.
EXXUA is expected to serve as a major growth catalyst as Aytu continues to build value for shareholders; the Company anticipates launching EXXUA in the fourth calendar quarter of 2025 as a centerpiece of its commercial efforts.
Conference call to discuss the EXXUA opportunity and commercialization plan scheduled for Wednesday, June 11, 2025, at 4:30 p.m. Eastern time.
Read MoreClick here to register
Discussion will focus on company's May 2025 meeting with the FDA to review the statistically significant responder analysis results for the subgroup of breast cancer patients in company's recently conducted Phase 3 OnTarget trial
The currently estimated US metastatic breast cancer population potentially qualifies as an orphan population, in alignment with company's core focus on orphan diseases
Company plans to promptly pursue authorization to initiate expanded access program for patients with breast cancer who may not be eligible for a potential pivotal treatment trial with crofelemer in patients with metastatic breast cancer
Read MoreProductive and collaborative discussion on proposed pathway by the company to bring crofelemer to approval for cancer therapy-related diarrhea (CTD) in patients with metastatic breast cancer receiving selected targeted therapies
The currently estimated US metastatic breast cancer population would qualify as an orphan population, which aligns with company's core focus on orphan diseases
Company plans to promptly pursue authorization to initiate expanded access program for patients with breast cancer who may not be eligible for a potential pivotal treatment trial with crofelemer in patients with metastatic breast cancer
Read More
Independent Global Study Evaluates EHR Satisfaction Across 110 Countries; 93% of European Users Say Dedalus Clinical Documentation Tools Better Align with Local Workflows than U.S. Vendors
Read More
Terrance Cole's First Test: Will He Restore DEA Diversion To Legitimacy
As the DEA Diversion spirals into constitutional crisis, all eyes now turn to incoming Administrator Terrance Cole. With the Supreme Court, DOJ, and Congress aligned on the illegality of the agency's ALJ system, Cole faces a clear mandate: dismantle the DEA's kangaroo court framework, remove corrupt leadership like Thomas Prevoznik, Matthew Strait and attorney Aarathi Haig, restore sound marijuana policy and return the agency to the rule of law. His next moves will determine whether the DEA Diversion can be salvaged-or whether it must be restructured from the ground up.
Read More
Independent Survey Reveals Gaps in Greek Healthcare IT, Underscoring Urgent Need for Homegrown Digital Solutions and Modernization Partnerships
Read MoreAytu enters the over $22 billion United States prescription major depressive disorder ("MDD") market with the first-in-class oral selective serotonin 5HT1a receptor agonist for adults with MDD.
EXXUA has demonstrated significant improvement in depression symptoms in clinical trials involving more than 5,000 patients and, notably, the incidence of sexual side effects experienced with EXXUA was comparable to placebo.
EXXUA is expected to serve as a major growth catalyst as Aytu continues to build value for shareholders; the Company anticipates launching EXXUA in the fourth calendar quarter of 2025 as a centerpiece of its commercial efforts.
EXXUA transaction financed by long-term, healthcare-focused institutional investors, including Aytu's largest shareholder Nantahala Capital Management, Stonepine Capital Management, Aytu management, and new institutional shareholders.
Read More
Terrance Cole, the nominee for Administrator of the U.S. Drug Enforcement Administration (DEA), stands at a pivotal juncture with the opportunity to address longstanding issues related to the agency's handling of cannabis policy.
Read More
The 2025 report, commissioned by the Alliance for International Exchange, provides further evidence of the key cultural and financial benefits of au pair programs for American families
Read MoreTreatment restored gene control, extended telomere length beyond healthy levels, reversed muscle and weight loss, reduced oxidative stress, and resulted in 100% survival - highlighting Telomir-1's potential to reverse key hallmarks of aging
Read MoreAI Nose accuracy in elderly care improved to 85% with additional Smell ID training
AI-friendly healthcare policies to provide tailwinds for commercial rollout
Read MoreLobe Sciences Ltd. has appointed Mr. Yong Yao as Chief Financial Officer and Executive Vice President, effective June 1, 2025, to lead the company's financial strategy during its next phase of growth.
Mr. Yao brings over 25 years of experience across finance and biotech, with executive roles at companies such as Mountain Valley MD and global firms like Scotiabank and Morgan Stanley.
His appointment marks a strategic shift to full-time financial leadership, aligning with Lobe's commitment to regulatory compliance, capital markets readiness, and operational expansion.
The DEA's In-House Forum Takes Another Hit
While the Department of Justice has withdrawn its defense of the DEA, the DEA continues to conduct hearings under this unconstitutional framework. Attorney General Pam Bondi wrote in her recent notice to the courts:
Read More"The Department has reviewed recent Supreme Court precedent and concluded that the existing structure of DEA's ALJs does not meet constitutional muster. Effective immediately, we will no longer defend this system in litigation and have notified federal courts accordingly."
"This award means our facilities have met rigorous, nationally recognized standards for quality and excellence," said Dr. Jessica Israel, Chief Medical and Innovation Officer at Complete Care Management
Read MoreCompany to meet with prospective partners as it accelerates toward IND submission for Telomir-1, with plans to begin human dosing in the first half of 2026
Read More
Duane Boise MMJ CEO opined “Now all eyes turn to DEA Administrator-nominee Terrance Cole. Thus far, his public marijuana statements have been evasive, his confirmation answers noncommittal, and his track record steeped in anti-cannabis fearmongering. However, as the DEA boss, he needs to stop the clown show in comparing cannabis to methamphetamine with no clinical basis and distributing memes claiming cannabis lowers sperm count by 50%, despite contradictory evidence”.
Read More
The Only Practice in Gilbert, Arizona, Honored in All Three Categories - Med Spa, Skin Care and Plastic Surgery - DrSkin Celebrates Statewide Support in Just Over Two Years of Innovation in Aesthetic Medicine
Read More
Launching Early Access for Brands, Creators, and Clinics to Deliver Precision Health at Scale
Founded by Stanford-trained longevity physician Dr. Hillary Lin, Elevate X enables brands, influencers, and clinicians to deliver precision health programs at scale, without building clinical operations from scratch
Read More
Located at The Ridge RTC campus in Milton, NH, the Emerging Adult Residential Treatment Program offers nine additional beds and tailored clinical support to an often underserved age group
Read MoreA unique oral drug candidate that is shown to restore vision and regenerate the retina in an animal model, addressing a major unmet need in ocular therapeutics
Read More
